Board Member
Kalaris Therapeutics, Inc. (KLRS)Chairman
Kalaris Therapeutics, Inc. (KLRS)Board Member
Seer, Inc. (SEER)Board Member
Scholar Rock Holding Corp (SRRK)Equibles does not estimate personal net worth.
Get an email with a short summary when Scholar Rock Holding Corp publishes a filing, an earnings call transcript or a press release.
Get SRRK alertsDavid Hallal is recorded as Board Member at Scholar Rock Holding Corp (SRRK) since January 1, 2017, CEO at Scholar Rock Holding Corp (SRRK), Board Member and Chairman at Kalaris Therapeutics, Inc. (KLRS) since March 18, 2025 and Board Member at Seer, Inc. (SEER) since January 1, 2018. The newest filing on record that lists David Hallal as CEO and Board Member at Scholar Rock Holding Corp (SRRK) is dated April 22, 2026. The newest filing on record that lists David Hallal as Board Member at Seer, Inc. (SEER) is dated May 28, 2025. Scholar Rock Holding Corp reported in an 8-K filed April 28, 2025 that David Hallal was appointed Chief Executive Officer, effective April 27, 2025. Kalaris Therapeutics, Inc. reported in an 8-K filed March 18, 2025 that David Hallal was appointed Chair of the Board, effective March 18, 2025. The proxy statement of Kalaris Therapeutics, Inc. reports total compensation of $15,258,586 for David Hallal in fiscal 2020, including a base salary of $566,500. Disclosed compensation is on record for 2 fiscal years. David Hallal has spoken on 6 earnings calls and 3 other investor events across 1 company, most recently for Scholar Rock Holding Corp on August 12, 2026. Scholar Rock Holding Corp is classified in the Biotechnology industry within the Healthcare sector. Kalaris Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Scholar Rock Holding Corp includes Dr. Jay Backstrom (CEO and Board Member), Jay Backstrom, M.D., M.P.H. (CEO and Board Member), Nagesh K. Mahanthappa Ph.D (CEO) and 7 others.
“On April 26, 2025, the Board of Directors (the “Board”) of Scholar Rock Holding Corporation and Scholar Rock, Inc. (collectively, the “Company”) appointed Mr. David Hallal as Chief Executive Officer of the Company effective as of April 27, 2025 (the “Transition Date”) following Dr. Jay T. Backstrom’s transition from his role as the Company’s Chief Executive Officer and President to Senior Advisor on the Transition Date.”
“Also as of the Effective Time, David Hallal was appointed Chair of the Board.”
“Well, thanks, Gary, and it's wonderful to be with all of your clients here at the conference. And as I was noting, it's always fun when it's a home game for us, just across town from Cambridge to Boston.”
“Today, Scholarock is operating from a position of strength as we enter a defining period for our company and for the SMA community. Across the business, we are executing with focus, discipline, and urgency as we drive towards the U.S. launch of Epidigromab this quarter.”
“And maybe where I'll start, Tommy, is that really before 2016, you know, SMA, a devastating, really was in the very last decade what we've seen, phase of innovation, the treatment of patients with SMA, all focused on motor neurons.”
“It's great to be here at Jeffries once again. We are extraordinarily excited at Scholarock today as 2026 sets up to be a transformative year for the company.”
“Scholar Rock is positioned for a pivotal year ahead. To that end, today, I am very pleased to announce that the FDA has accepted for review our biologics license application for apitegromab for the treatment of children and adults living with SMA.”
2025-03-18–present
2025-03-18–present
2018-01-01–present
Last confirmed May 28, 2025
2017-01-01–present
Last confirmed April 22, 2026
Start not stated–present
Last confirmed April 22, 2026
Start not stated–2021-04-12
Last confirmed by a filing; no departure on record
Biotechnology · Healthcare
CEO, Board Member
2017-01-01–present
Biotechnology · Healthcare
Board Member, Chairman
2025-03-18–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2020 | Kalaris Therapeutics, Inc. (KLRS) | Chairman and Former Chief Executive Office r | $566,500 | $15,258,586 |
| 2019 | Kalaris Therapeutics, Inc. (KLRS) | Chief Executive Officerand Chairman | $550,000 | $3,565,110 |
